CULLINAN THERAPEUTICS, INC. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
CULLINAN THERAPEUTICS, INC. (CGEM) had Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment of $969.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment · last filed 2026-03-10
- 2025-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $969.00K.
- 2024-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $658.00K.
- 2023-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $352.00K.
- 2022-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $135.00K.
| Period end | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment |
|---|---|
| 2025-12-31 | $969.00K 10-K · filed 2026-03-10 |
| 2024-12-31 | $658.00K 10-K · filed 2026-03-10 |
| 2023-12-31 | $352.00K 10-K · filed 2025-02-27 |
| 2022-12-31 | $135.00K 10-K · filed 2024-03-14 |
| 2021-12-31 | $232.00K 10-K · filed 2023-03-09 |
| 2020-12-31 | $179.00K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |